|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1995-4-12
|
|
pubmed:abstractText |
Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occurred in six out of the 20 patients (30%, 95% confidence interval 12-54%) and there were 12 partial responders (60%, 95% confidence interval 37-81%), thus giving an overall response rate of 90% (95% confidence interval 63-97%). Two patients had progressive disease. The median duration of response for those patients with metastatic disease was 7.3 (1.3-20.1+) months. The median survival time for these patients was 15 (5.3-27.9+) months. Of the four patients treated with locally advanced disease three achieved a complete clinical response and one a partial response. Three out of four of these patients subsequently underwent a mastectomy, and in one of these no viable tumour was seen. Our conclusion is that this regimen is excellent palliation for metastatic disease and possibly useful neoadjuvant treatment.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1285731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1518100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1727912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1735880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1782080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-1960751,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-2110860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-2165740,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-2458438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-2650758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-2829955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-3279894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-3318902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-3806159,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-3819804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-6387060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-7049347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-7285274,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-7348580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-8080512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7533518-912660
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
610-3
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7533518-Adult,
pubmed-meshheading:7533518-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7533518-Breast Neoplasms,
pubmed-meshheading:7533518-Drug Administration Schedule,
pubmed-meshheading:7533518-Epirubicin,
pubmed-meshheading:7533518-Female,
pubmed-meshheading:7533518-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7533518-Humans,
pubmed-meshheading:7533518-Ifosfamide,
pubmed-meshheading:7533518-Mesna,
pubmed-meshheading:7533518-Middle Aged,
pubmed-meshheading:7533518-Neoplasm Metastasis,
pubmed-meshheading:7533518-Neutropenia
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
|
|
pubmed:affiliation |
Department of Clinical Oncology, Newcastle General Hospital, Newcastle upon Tyne, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
